BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25938351)

  • 21. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
    Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
    Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
    Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
    Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors.
    Alkhasawneh A; Reith JD; Toro TZ; Ayed AO; Lu X; George TJ; Duckworth LV
    Am J Clin Pathol; 2015 Mar; 143(3):385-92. PubMed ID: 25696796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting.
    Harvey J; Thomas C; Wood B; Hardie M; Dessauvagie B; Combrinck M; Frost FA; Sterrett G
    Pathology; 2015 Jan; 47(1):13-20. PubMed ID: 25474507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining.
    Dessauvagie B; Thomas A; Thomas C; Robinson C; Combrink M; Budhavaram V; Kunjuraman B; Meehan K; Sterrett G; Harvey J
    Pathology; 2019 Dec; 51(7):681-687. PubMed ID: 31630876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
    Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
    Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
    Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
    Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ.
    Bosch DE; Kilgore MR; Schmidt RA; Swanson PE; Rendi MH; Chang OH
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):543-547. PubMed ID: 28885232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas.
    Tsuta K; Liu DC; Kalhor N; Wistuba II; Moran CA
    Am J Clin Pathol; 2011 Aug; 136(2):252-9. PubMed ID: 21757598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
    Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC
    Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency.
    Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P
    Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors.
    Hacking SM; Sajjan S; Lee L; Ziemba Y; Angert M; Yang Y; Jin C; Chavarria H; Kataria N; Jain S; Nasim M
    Pathol Res Pract; 2020 Mar; 216(3):152753. PubMed ID: 31761497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
    Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
    Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
    Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
    Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
    Tracht J; Zhang K; Peker D
    J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
    Kim YJ; Ketter R; Steudel WI; Feiden W
    Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
    Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
    J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
    Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
    Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.